<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>RATIONALE: <z:hpo ids='HP_0002617'>Aneurysm</z:hpo> and dissection of the ascending thoracic aorta are the main cardiovascular complications of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) resulting in premature <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Studies using mouse models of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> have shown that activation of transforming growth factor-beta (TGF-β) and the concomitant upregulation of matrix metalloproteinases (MMPs) contribute to <z:hpo ids='HP_0002617'>aneurysm</z:hpo> development </plain></SENT>
<SENT sid="2" pm="."><plain>Our previous study showed that <z:chebi fb="1" ids="50845">doxycycline</z:chebi> delayed <z:hpo ids='HP_0002617'>aneurysm</z:hpo> rupture in a mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, Fbn1(mgR/mgR) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi> has been shown to prevent <z:hpo ids='HP_0002617'>aneurysms</z:hpo> in another mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, Fbn1(C1039G/+), through inhibition of the Erk1/2 pathway </plain></SENT>
<SENT sid="4" pm="."><plain>However, the role of MMP-2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and effect of <z:chebi fb="0" ids="6541">losartan</z:chebi> on the lifespan of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> mice remain unknown </plain></SENT>
<SENT sid="5" pm="."><plain>OBJECTIVE: We investigated the role of MMP-2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and compared the effects of <z:chebi fb="0" ids="6541">losartan</z:chebi> and <z:chebi fb="1" ids="50845">doxycycline</z:chebi> on <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> and survival in Fbn1(mgR/mgR) mice </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS AND RESULTS: By life table analysis, we found that <z:chebi fb="0" ids="6541">losartan</z:chebi> and <z:chebi fb="1" ids="50845">doxycycline</z:chebi> improved the survival of Fbn1(mgR/mgR) mice </plain></SENT>
<SENT sid="7" pm="."><plain>Gelatin zymography and Western blot data showed that only <z:chebi fb="1" ids="50845">doxycycline</z:chebi> inhibited MMP-2 expression, whereas both drugs decreased Erk1/2 phosphorylation </plain></SENT>
<SENT sid="8" pm="."><plain>When combined, only one of nine mice died within the 30-week study; aortic histology and diameter were normalized and the effects on Smad2 phosphorylation was additive </plain></SENT>
<SENT sid="9" pm="."><plain>To further explore the role of MMP-2 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, we created MMP-2-deficient Fbn1(mgR/mgR) mice </plain></SENT>
<SENT sid="10" pm="."><plain>MMP-2 deletion inhibited activation of TGF-β and phosphorylation of Erk1/2 and Smad2 and prolonged the lifespan of the mice </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These studies demonstrated that inhibition of MMP-2 by <z:chebi fb="1" ids="50845">doxycycline</z:chebi> delayed the manifestations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, in part, through its ability to decrease active TGF-β and the noncanonical signaling cascade downstream of TGF-β </plain></SENT>
<SENT sid="12" pm="."><plain>This study further suggested that targeting TGF-β signaling at different points might be a more effective strategy for inhibiting disease progression </plain></SENT>
</text></document>